SCHEMBL3165877

SCHEMBL3165877

CCn1cc(C(=O)O)cc(Cl)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.44
ALDH1A1 P00352 2/20 0.42
PKM P14618 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TTR P02766 1/20 0.41
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 2/20 0.38
MAPK10 P53779 1/20 0.38
TPMT P51580 2/20 0.37
SRD5A2 P31213 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
EGLN1 Q9GZT9 2/20 0.36
PLAU P00749 1/20 0.36
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16759801 0.82 ALDH1A1 (0.40) P2RX7ALDH1A1PKMMEN1KMT2A
SCHEMBL3164617 0.81 POLB (0.39) ALDH1A1PKMMEN1KMT2ATTR
SCHEMBL3164712 0.79 POLB (0.38) ALDH1A1TSHRPOLBMAPK10RAB9A
SCHEMBL16100884 0.77 RAF1 (0.41) EGLN1
SCHEMBL480184 0.77 TTR (0.45) P2RX7MEN1KMT2ATTRTSHR
SCHEMBL4479607 0.76 P2RX7 (0.67) P2RX7ALDH1A1PKMMEN1KMT2A
SCHEMBL14372203 0.76 MEN1 (0.37) ALDH1A1MEN1KMT2ATSHRATM
SCHEMBL2525802 0.75 ALDH1A1 (0.54) P2RX7ALDH1A1PKMTSHRCYP3A4
SCHEMBL7508385 0.74 ATM (0.69) P2RX7ALDH1A1PKMMEN1KMT2A
SCHEMBL20704421 0.73 GRIA1 (0.33) P2RX7ALDH1A1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138525-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-21 US claimed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 CN claimed
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP claimed
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders MSD K.K. (JP) 2005-01-13 US claimed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 WO claimed
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives MSD K.K. (JP) 2004-04-15 US claimed
EP-1546133-B1 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMA CO LTD (JP) 2010-03-17 EP disclosed
CN-100528864-C N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2009-08-19 CN disclosed
US-7138525-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-21 US disclosed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 CN disclosed
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP disclosed
US-6869966-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-03-22 US disclosed
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders MSD K.K. (JP) 2005-01-13 US disclosed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 WO disclosed
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives MSD K.K. (JP) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders NPY1R, NPY2R, NPY4R P2RX7 1522/4885ALDH1A1 3552/4885PKM 3250/4885
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives GPR119, NPY4R, NPY1R P2RX7 1783/4885ALDH1A1 4001/4885PKM 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.